Pharming Group’s business model is grounded in rare disease biopharma with a focus on niche, high-value therapies protected by regulatory exclusivities and orphan drug designations. Its differentiation stems from combining proprietary biologics and precision medicine with advanced patient identific…
Pharming Group (PHAR) Q4 2024: 21% Revenue Growth Accelerates Rare Disease Portfolio Expansion
Pharming delivered robust 21% revenue growth in 2024, driven by record RUCONEST® sales and rapid Joenja® adoption. The recent Abliva acquisition adds a pivotal mitochondrial disease asset, signaling a strategic pivot toward broader rare disease leadership. Continued patient identification and regulatory progress underpin strong 2025 momentum and pipeline expansion.
Summary
- Rare Disease Leadership Build: Strategic acquisition and pipeline diversification reinforce Pharming’s global rare disease positioning.
- Commercial Momentum: Sustained RUCONEST® growth and accelerating Joenja® uptake validate core franchise strength.
- Pipeline Expansion: Advancement of leniolisib in broader primary immunodeficiencies and pediatric indications drives long-term growth potential.
Business Overview
Pharming Group N.V. is a biopharmaceutical company focused on rare diseases, commercializing protein replacement therapies and precision medicines. Its primary revenue drivers are RUCONEST®, an acute treatment for hereditary angioedema (HAE), and Joenja® (leniolisib), a disease-modifying therapy for activated PI3K delta syndrome (APDS). The company also recently acquired Abliva AB, adding KL1333, a drug candidate for mitochondrial DNA-driven primary mitochondrial diseases, to its late-stage clinical pipeline.
Performance Analysis
Pharming’s full-year 2024 revenues increased by 21% to $297.2 million, surpassing guidance and reflecting strong underlying demand. RUCONEST® sales rose 11% to $252.2 million, supported by a 24% increase in new patient enrollments and an 11% expansion in the physician prescriber base in the US, which accounts for 98% of RUCONEST® revenues. Joenja® revenues surged 147% to $45 million in its first full year post-launch, fueled by growth in the US and expanded access programs globally.
Gross profit rose 19% to $261.8 million despite a 40% increase in cost of sales, partly due to higher production costs and one-time inventory impairments. Operating expenses increased 10%, driven by investments in Joenja®, R&D for pipeline expansion, and integration costs related to Abliva. The company reported operating profit for the second consecutive quarter in Q4 2024, reflecting disciplined expense management alongside growth.
- Patient Identification and Enrollment Growth: Over 880 diagnosed APDS patients globally, with ongoing efforts to reclassify variants of uncertain significance (VUS) expected to significantly expand the addressable market.
- Geographic Expansion: Joenja® regulatory approvals and reimbursement progress in the UK, Japan, Australia, and Canada set the stage for international launches in 2025 and beyond.
- Pipeline Advancement: Two Phase II trials initiated for leniolisib in broader primary immunodeficiencies with immune dysregulation and common variable immunodeficiency (CVID), targeting substantially larger patient populations.
Overall, Pharming demonstrated strong commercial execution with expanding patient access, while investing strategically in pipeline and geographic growth to sustain long-term value creation.
Executive Commentary
"The strength of the results presented today, with record RUCONEST® revenue and strong Joenja® growth, is testament to Pharming’s momentum... We enter 2025 with a number of regulatory reviews for leniolisib ongoing as we prepare for launches in key markets and for pediatrics. We also advanced our efforts to expand the addressable patient population for leniolisib... The acquisition of Abliva adds a potential first-in-disease treatment for primary mitochondrial diseases, which has the opportunity to further transform Pharming’s growth trajectory."
Fabrice Chouraqui, CEO
"Q4 was a very robust quarter for Pharming. Revenues grew by 14% versus a very strong fourth quarter in 2023. Operating profit increased by $5.6 million, driven by higher gross profit and active OPEX management. For 2025, we expect total revenues between $315 million and $335 million, implying 6% to 13% growth, with operating expenses flat excluding Abliva-related costs."
Jeroen Wackermann, CFO
Strategic Positioning
1. Expanding Core Franchise with RUCONEST®
RUCONEST® remains a cornerstone of Pharming’s portfolio, delivering 11% revenue growth in 2024 driven by increased prescriber penetration and new patient enrollments. Its unique mode of action targeting multiple inflammatory cascades provides a differentiated value proposition, especially for patients refractory to other therapies. Management’s confidence in RUCONEST®’s sustained growth amid new market entrants is underpinned by strong physician feedback and market research, suggesting ongoing expansion opportunities within the acute HAE treatment landscape.
2. Scaling Joenja® Through Patient Identification and Geographic Expansion
Joenja®’s 147% revenue growth reflects successful commercialization in the US with 96 patients on paid therapy and a robust pipeline of over 188 patients under access programs globally. Key growth drivers include ongoing efforts to resolve VUS in APDS genetics, which could significantly increase the diagnosed patient base, and upcoming regulatory launches in the UK, Japan, Canada, and Australia. The expected pediatric label expansion in 2026 further broadens the addressable market, positioning Joenja® as a high-growth precision medicine franchise.
3. Pipeline Diversification via Abliva Acquisition
The acquisition of Abliva and its lead asset KL1333 represents a strategic pivot to mitochondrial DNA-driven primary mitochondrial diseases, a rare disorder with an estimated 30,000 addressable patients in major markets. KL1333 is in a pivotal Phase III trial with positive interim results and Fast Track designation, offering blockbuster potential. This acquisition complements Pharming’s existing portfolio and leverages its rare disease expertise, infrastructure, and commercial capabilities to accelerate growth beyond current franchises.
4. Advancing Leniolisib in Broader Primary Immunodeficiencies
Pharming is progressing two Phase II trials targeting genetically defined primary immunodeficiencies with immune dysregulation and CVID, which represent significantly larger patient populations than APDS alone. These programs are designed to explore safety, tolerability, and efficacy, with the FDA granting Fast Track designation for the genetically defined PID indication. Successful expansion into these indications could transform leniolisib into a blockbuster asset and significantly enhance Pharming’s long-term growth profile.
5. Financial Discipline and Operational Efficiency
Despite increased R&D and integration costs, Pharming maintained disciplined operating expense management, resulting in operating profit for the second consecutive quarter. The company’s strong cash position and positive operating cash flow support continued investment in pipeline advancement and geographic expansion without dilutive financing. Management’s guidance for flat operating expenses excluding Abliva-related costs reflects a focus on cost control amid growth initiatives.
Key Considerations
Pharming’s 2024 results reflect a company executing a multi-pronged growth strategy in rare diseases, balancing commercial momentum with pipeline expansion and strategic acquisitions.
Key Considerations:
- Patient Identification Scale-Up: The resolution of VUS genetic variants is a critical catalyst for expanding the APDS patient pool and accelerating Joenja® uptake.
- Regulatory Milestones: Approvals and reimbursement decisions in key markets including the UK, Japan, and Canada will materially affect international revenue growth trajectories.
- Pipeline De-Risking: Early Phase II data and regulatory designations for leniolisib’s new indications are pivotal to validating blockbuster potential beyond APDS.
- Integration of Abliva: Effective integration and enrollment acceleration in the KL1333 pivotal trial are essential to realizing mitochondrial disease opportunity.
- Operational Leverage: Maintaining operating expense discipline while investing in growth will be key to improving profitability and cash flow.
Risks
Pharming faces typical biotech risks including clinical trial execution uncertainties, regulatory approval timelines, and market adoption challenges for new indications. The company also monitors potential US tariff impacts on supply chain costs but currently reports no inventory build-up or material exposure. Integration risks related to Abliva and the ability to convert expanded access patients to paid therapy remain key operational considerations.
Forward Outlook
For Q1 2025, Pharming expects continued revenue growth driven by RUCONEST® and Joenja®, with operating expenses stable excluding Abliva integration costs. Full-year 2025 revenue guidance is set between $315 million and $335 million, implying 6% to 13% growth. Management anticipates accelerated Joenja® growth in H2 2025 from VUS patient reclassification and geographic launches. Operating expenses are expected to include approximately $30 million related to Abliva, including $17 million in R&D and non-recurring integration costs. The company plans to update on Abliva-related expenses in Q1 2025 results.
Takeaways
Pharming’s fourth quarter and full-year 2024 results underscore a rare disease company transitioning from foundational commercial success to a diversified growth platform.
- Commercial Execution Drives Revenue Growth: RUCONEST® and Joenja® growth validate Pharming’s patient identification and market expansion strategies, bolstering near-term revenue visibility.
- Pipeline and Acquisition Expand Long-Term Potential: The addition of KL1333 and leniolisib’s new indications position Pharming for multi-asset, multi-indication growth beyond its legacy franchises.
- Financial Discipline Supports Sustainable Investment: Positive operating profit and cash flow in recent quarters reflect management’s focus on balancing growth investments with cost control, enhancing financial resilience.
Conclusion
Pharming’s 2024 performance and strategic initiatives position the company well to capitalize on growing rare disease markets. The integration of Abliva and expansion of leniolisib indications mark important inflection points, while strong execution in RUCONEST® and Joenja® commercialization provides a solid financial foundation. Investors should monitor patient identification progress, regulatory milestones, and pipeline trial readouts as key drivers of future value creation.
Industry Read-Through
Pharming’s successful expansion from a single-product rare disease company to a diversified portfolio with multiple late-stage assets exemplifies the evolving biopharma landscape prioritizing precision medicine and orphan drug development. The company’s approach to patient identification through genetic variant reclassification highlights a broader industry trend toward leveraging genomic data to unlock new markets. Additionally, the strategic acquisition of mitochondrial disease assets signals growing interest in rare metabolic disorders, an area gaining attention across biotech. Pharming’s disciplined balance of commercial growth and pipeline investment provides a model for sustainable value creation in the competitive rare disease sector.